Perjeta

Perjeta Indications/Uses

pertuzumab

Manufacturer:

Roche

Distributor:

DKSH
Full Prescribing Info
Indications/Uses
Metastatic Breast Cancer: Perjeta is indicated in combination with Herceptin (trastuzumab) and docetaxel for patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Early Breast Cancer: Perjeta is indicated in combination with Herceptin and chemotherapy for the: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer (see Dosage & Administration and Pharmacology: Pharmacodynamics: Clinical/Efficacy Studies under Actions).
Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. (See Pharmacology: Pharmacodynamics: Clinical/Efficacy Studies under Actions.)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in